841 related articles for article (PubMed ID: 33157919)
1. Ixazomib-associated tumor lysis syndrome in multiple myeloma: A case report.
Jin F; Yang M; Chen Y; Jiang L; Liu L
Medicine (Baltimore); 2020 Nov; 99(45):e22632. PubMed ID: 33157919
[TBL] [Abstract][Full Text] [Related]
2. High Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib.
Oiwa K; Morita M; Kishi S; Okura M; Tasaki T; Matsuda Y; Tai K; Hosono N; Ueda T; Yamauchi T
Anticancer Res; 2016 Dec; 36(12):6655-6662. PubMed ID: 27919998
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib-associated tumor lysis syndrome.
Shely RN; Ratliff PD
Pharmacotherapy; 2014 May; 34(5):e34-7. PubMed ID: 24390940
[TBL] [Abstract][Full Text] [Related]
5. Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient.
Steiner RE; Orlowski RZ; Lee HC
Acta Haematol; 2018; 139(1):67-70. PubMed ID: 29402766
[TBL] [Abstract][Full Text] [Related]
6. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
[TBL] [Abstract][Full Text] [Related]
7. Acute kidney injury in bortezomib-treated patients with multiple myeloma.
Song SM; Jeon J; Jang HR; Kim K; Huh W; Kim YG; Lee JE
Nephrol Dial Transplant; 2023 Aug; 38(9):2077-2085. PubMed ID: 36662030
[TBL] [Abstract][Full Text] [Related]
8. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Dimopoulos MA; Laubach JP; Echeveste Gutierrez MA; Grzasko N; Hofmeister CC; San-Miguel JF; Kumar S; Labotka R; Lu V; Berg D; Byrne C; Teng Z; Liu G; van de Velde H; Richardson PG
Eur J Haematol; 2019 Jun; 102(6):494-503. PubMed ID: 30943323
[TBL] [Abstract][Full Text] [Related]
9. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
11. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Richardson PG; Kumar SK; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Gimsing P; Garderet L; Touzeau C; Buadi FK; Laubach JP; Cavo M; Darif M; Labotka R; Berg D; Moreau P
J Clin Oncol; 2021 Aug; 39(22):2430-2442. PubMed ID: 34111952
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib-induced tumor lysis syndrome in relapsed multiple myeloma: a report of two cases.
Terzi Demirsoy E; Birtas Atesoglu E; Eren N; Gedük A; Mehtap O; Tarkun P; Hacıhanefioğlu A
Tumori; 2019 Dec; 105(6):NP24-NP27. PubMed ID: 30580656
[TBL] [Abstract][Full Text] [Related]
13. Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.
Sokol J; Guman T; Chudej J; Hlebaskova M; Stecova N; Valekova L; Kucerikova M; Stasko J
Ann Hematol; 2022 Jan; 101(1):81-89. PubMed ID: 34550463
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.
Kumar SK; LaPlant BR; Reeder CB; Roy V; Halvorson AE; Buadi F; Gertz MA; Bergsagel PL; Dispenzieri A; Thompson MA; Crawley J; Kapoor P; Mikhael J; Stewart K; Hayman SR; Hwa YL; Gonsalves W; Witzig TE; Ailawadhi S; Dingli D; Go RS; Lin Y; Rivera CE; Rajkumar SV; Lacy MQ
Blood; 2016 Nov; 128(20):2415-2422. PubMed ID: 27702799
[TBL] [Abstract][Full Text] [Related]
15. Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.
Mina R; Falcone AP; Bringhen S; Liberati AM; Pescosta N; Petrucci MT; Ciccone G; Capra A; Patriarca F; Rota-Scalabrini D; Bonello F; Musolino C; Cea M; Zambello R; Tacchetti P; Belotti A; Cellini C; Paris L; Grasso M; Aquino S; De Paoli L; De Sabbata G; Ballanti S; Offidani M; Boccadoro M; Monaco F; Corradini P; Larocca A
Blood Cancer J; 2021 Dec; 11(12):197. PubMed ID: 34876566
[No Abstract] [Full Text] [Related]
16. Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.
Kondo M; Hotta Y; Yamauchi K; Sanagawa A; Komatsu H; Iida S; Kimura K
BMC Cancer; 2020 Nov; 20(1):1117. PubMed ID: 33203424
[TBL] [Abstract][Full Text] [Related]
17. Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System.
Sanagawa A; Hotta Y; Kondo M; Nishikawa R; Tohkin M; Kimura K
Anticancer Drugs; 2020 Feb; 31(2):183-189. PubMed ID: 31789626
[TBL] [Abstract][Full Text] [Related]
18. Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma.
Ohashi Y; Yatabe M; Niijima D; Tani K; Ogawa C; Yachi Y; Kagoo T; Boku S; Ueno H; Yano T; Higai K; Yokoyama A
In Vivo; 2020; 34(5):2821-2828. PubMed ID: 32871820
[TBL] [Abstract][Full Text] [Related]
19. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Dimopoulos MA; Grosicki S; Jędrzejczak WW; Nahi H; Gruber A; Hansson M; Gupta N; Byrne C; Labotka R; Teng Z; Yang H; Grzasko N; Kumar S
Eur J Cancer; 2019 Jan; 106():89-98. PubMed ID: 30471652
[TBL] [Abstract][Full Text] [Related]
20. Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
Suzuki K; Terui Y; Nishimura N; Ueda K; Mishima Y; Sakajiri S; Yokoyama M; Aiba K; Hatake K
Jpn J Clin Oncol; 2014 May; 44(5):435-41. PubMed ID: 24664944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
